April 8 Product: Supernus Pharmaceuticals SPN-830 Indication: Parkinsons disease Supernus Pharmaceuticals failed, for the second time, to secure approval for its drug-device combo SPN-830, which is intended for the continuous treatment of motor fluctuations in Parkinsons disease
moreover, as individual heterogeneity is very obvious, more data is needed to support it
BPC 157 continued: review of human evidence, lack of replication of animal data, safety considerations, risk-reward analysis, and why it belongs in bucket #1 [1:03:15]
Progress photos taken under consistent lighting conditions help visualize changes
It is designed for intramuscular or subcutaneous use, supporting red blood cell production and managing absorption issues, and requires a valid veterinary prescription